Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  • Dick de Zeeuw
  • Tadao Akizawa
  • Rajiv Agarwal
  • Paul Audhya
  • George L Bakris
  • Melanie Chin
  • Melissa Krauth
  • Hiddo J Lambers Heerspink
  • Colin J Meyer
  • John J McMurray
  • Hans-Henrik Parving
  • Pablo E Pergola
  • Giuseppe Remuzzi
  • Robert D Toto
  • Nosratola D Vaziri
  • Christoph Wanner
  • David G Warnock
  • Janet Wittes
  • Glenn M Chertow
Vis graf over relationer
Chronic kidney disease (CKD) associated with type 2 diabetes mellitus constitutes a global epidemic complicated by considerable renal and cardiovascular morbidity and mortality, despite the provision of inhibitors of the renin-angiotensin-aldosterone system (RAAS). Bardoxolone methyl, a synthetic triterpenoid that reduces oxidative stress and inflammation through Nrf2 activation and inhibition of NF-κB was previously shown to increase estimated glomerular filtration rate (eGFR) in patients with CKD associated with type 2 diabetes mellitus. To date, no antioxidant or anti-inflammatory therapy has proved successful at slowing the progression of CKD.
OriginalsprogEngelsk
TidsskriftAmerican Journal of Nephrology
Vol/bind37
Udgave nummer3
Sider (fra-til)212-22
Antal sider11
ISSN0250-8095
DOI
StatusUdgivet - 2013

ID: 38879053